What is NGX Bio?
NGX Bio operates as a specialized marketplace designed to streamline the procurement of genomic sequencing services. Founded by Stanford academics, the organization was established to mitigate the extreme variability in cost and data quality prevalent in the sequencing market. By aggregating demand and acting as a repeat customer, NGX Bio ensures that researchers receive consistent, high-quality data while benefiting from economies of scale. Following its 2019 acquisition by Admera Health, the company has evolved into a comprehensive provider of NGS-based products and solutions, leveraging a vast network of partners to support diverse biological research initiatives. Its core value proposition remains the democratization of access to reliable, affordable, and rapid sequencing capacity for the global scientific community.
How much funding has NGX Bio raised?
NGX Bio has raised a total of $3M across 1 funding round:
Private Equity
$3M
Private Equity (2017): $3M with participation from Third Kind Venture Capital, Berkeley Angel Network, 180 Degree Capital Corp, Band of Angels, and Lateral Capital
Key Investors in NGX Bio
Third Kind Venture Capital
Third Kind Venture Capital is a venture capital firm specializing in early-stage investments, with a primary focus on the consumer internet, software, and financial services sectors.
Berkeley Angel Network
The Berkeley Angel Network is a collective of alumni and faculty from UC Berkeley dedicated to fostering entrepreneurship and supporting companies that utilize university-developed technology.
180 Degree Capital Corp
180 Degree Capital Corp. specializes in identifying and investing in micro-cap stocks, employing a constructive activist approach to unlock value in undervalued companies.
What's next for NGX Bio?
With the backing of major institutional and angel investors, NGX Bio is well-positioned to scale its integrated service model under the Admera Health umbrella. The strategic focus moving forward involves deepening its technological infrastructure to support more complex genomic workflows and expanding its partner network to meet the rising demand for precision medicine. As the genomics industry continues to mature, NGX Bio is expected to leverage its established market intelligence to drive further innovation in sample preparation and data management, ensuring that it remains a critical node in the life sciences research ecosystem.
See full NGX Bio company page
